BCTX Projected Dividend Yield
Briacell Therapeutics Corp (New) ( NASDAQ : BCTX )BriaCell Therapeutics is an immuno-oncology biotechnology company focusing on cancer immunotherapy. Co. owns the U.S. patent to SV-BR-1-GM ("Bria-IMT™"), a whole-cell targeted immunotherapy for cancer (U.S. Patent No. 7,674,456), as well as patents related to PKCd inhibitors (U.S. Patent Nos. 9,364,460 and 9,572,793). Co. advances its Bria-IMT targeted immunotherapy program against end-stage breast cancer to Phase 3 study. Co. develops off-the-shelf immunotherapy, Bria-OTS™, and a soluble CD80 protein therapeutic which acts both as a stimulator of the immune system as well as an immune checkpoint inhibitor. 20 YEAR PERFORMANCE RESULTS |
BCTX Dividend History Detail BCTX Dividend News BCTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |